Neurotech International has secured ethics approval to commence a pharmacokinetic study of NTI164 in healthy adults, a crucial step for regulatory compliance.
Neurotech International is progressing with trials of NTI164, a drug targeting pediatric neurological disorders, showing potential in improving neural network function.
InhaleRx's IRX-211 drug-device combination has been approved for a Phase II clinical trial to treat breakthrough cancer pain (BTcP) in patients, addressing a critical need for non-opioid options.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.